secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0001564590-22-009483
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Achieve Life Sciences reports FY2021 net loss $33.2M; Phase 3 ORCA-2 topline data expected Q2 2022
--------------------------------------------------------------------------------

- Cash, cash equivalents and restricted cash of $43.1M as of Dec 31, 2021.
- Total operating expenses for FY2021 were $33.1M; net loss $33.2M.
- Initiated Phase 3 ORCA-3 trial; ORCA-2 completed with topline results due Q2 2022.
- Entered $25M loan facility with Silicon Valley Bank in December 2021.
- FDA accepted IND for cytisinicline in e-cigarette/vaping cessation; Phase 2 ORCA-V1 expected Q2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000156459022009483/0001564590-22-009483-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000156459022009483/achv-8k_20220310.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-009483

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer